Arthritis clinical trials at UC Irvine

2 in progress, 1 open to eligible people

Showing trials for

  • NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

    open to eligible people ages 18-75

    This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

    Orange, California and other locations

  • BMS-986278 in Participants With Progressive Pulmonary Fibrosis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

    Newport Beach, California and other locations

Our lead scientists for Arthritis research studies include .

Last updated: